Home > Publications Database > Heterogeneity of anti-Caspr2 antibodies: specificity and pathogenicity. > print

001     282556
005     20251218103442.0
024 7 _ |a 10.1038/s41398-025-03677-w
|2 doi
024 7 _ |a pmid:41257955
|2 pmid
024 7 _ |a pmc:PMC12644748
|2 pmc
037 _ _ |a DZNE-2025-01319
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Su, Julia
|b 0
245 _ _ |a Heterogeneity of anti-Caspr2 antibodies: specificity and pathogenicity.
260 _ _ |a London
|c 2025
|b Nature Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1764680674_28229
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Maternal anti-Caspr2 (Contactin-associated protein-like 2) antibodies have been associated with increased risk for autism spectrum disorder (ASD). Previous studies have shown that in utero exposure to anti-Caspr2 antibodies results in a phenotype with ASD-like features in male mice. Here we ask whether four newly generated antibodies against Caspr2 are pathogenic to the developing fetal brain and whether they function through similar means. Our results show that these novel anti-Caspr2 antibodies recognize different epitopes of Caspr2. In utero exposure to these antibodies elicits differential behavioral phenotypes in male offspring, as demonstrated in the social interaction task, as well as phenotypic alterations in the open-field and light-dark tasks. These results demonstrate variability in the antigenic specificity and pathogenicity of anti-Caspr2 antibodies which may have clinical implications.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Nerve Tissue Proteins
|2 NLM Chemicals
650 _ 7 |a Membrane Proteins
|2 NLM Chemicals
650 _ 7 |a Autoantibodies
|2 NLM Chemicals
650 _ 7 |a CNTNAP2 protein, mouse
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Nerve Tissue Proteins: immunology
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Autism Spectrum Disorder: immunology
|2 MeSH
650 _ 2 |a Membrane Proteins: immunology
|2 MeSH
650 _ 2 |a Pregnancy
|2 MeSH
650 _ 2 |a Autoantibodies: immunology
|2 MeSH
650 _ 2 |a Prenatal Exposure Delayed Effects: immunology
|2 MeSH
650 _ 2 |a Behavior, Animal
|2 MeSH
650 _ 2 |a Brain: immunology
|2 MeSH
650 _ 2 |a Brain: embryology
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
700 1 _ |a Gupta, Rohan
|b 1
700 1 _ |a van Hoof, Scott
|0 P:(DE-2719)2812820
|b 2
|u dzne
700 1 _ |a Kreye, Jakob
|0 P:(DE-2719)2811468
|b 3
700 1 _ |a Prüß, Harald
|0 P:(DE-2719)2810931
|b 4
700 1 _ |a Spielman, Benjamin
|0 0000-0002-0634-8118
|b 5
700 1 _ |a Brimberg, Lior
|0 0000-0002-5262-3053
|b 6
700 1 _ |a Volpe, Bruce T
|0 0000-0002-1098-1848
|b 7
700 1 _ |a Huerta, Patricio T
|0 0000-0003-0270-2308
|b 8
700 1 _ |a Diamond, Betty
|0 0000-0002-3250-3804
|b 9
773 _ _ |a 10.1038/s41398-025-03677-w
|g Vol. 15, no. 1, p. 498
|0 PERI:(DE-600)2609311-X
|n 1
|p 498
|t Translational Psychiatry
|v 15
|y 2025
|x 2158-3188
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/282556/files/DZNE-2025-01319.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/282556/files/DZNE-2025-01319.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:282556
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2812820
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2811468
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2810931
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-12
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b TRANSL PSYCHIAT : 2022
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:46:03Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:46:03Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-12
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-12
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:46:03Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-12
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b TRANSL PSYCHIAT : 2022
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-12
920 1 _ |0 I:(DE-2719)1810003
|k AG Prüß
|l Autoimmune Encephalopathies
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1810003
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21